Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
---|
07/07/2004 | CN1156477C Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase |
07/07/2004 | CN1156471C 5-phridyl-1,3-azole compounds, process for producing the same and use thereof |
07/07/2004 | CN1156462C Antipsychotic cyclic N-aralkyl amines |
07/07/2004 | CN1156454C Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
07/07/2004 | CN1156452C Compound as anti-inflammatory agent |
07/07/2004 | CN1156451C Betz 2-adrenoceptor agonists |
07/07/2004 | CN1156445C Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isindoline derivatives |
07/07/2004 | CN1156290C Medicine for curing lupus erythematosus brain disease |
07/07/2004 | CN1156275C Application of chuanliansu as specific p-type calcium passage blocker |
07/06/2004 | US6759538 Substituted diphenyl heterocycles useful for treating HCV infection |
07/06/2004 | US6759535 A 3-amide-methyl- or 3-urea-isoquinoline derivatives, enzyme inhibitor of protein kinase, for treating cell proliferation, cell death, inflammatory diseases, autoimmune diseases, bone disorders, infectious diseases, viral diseases |
07/06/2004 | US6759534 Reacting benzofuran derivative with organolithium compound in presence of sulfur source; reacting with dichloropyridazine derivative, reacting with alkaline alkoxide in alkanol; reacting with mineral acid, oxidation |
07/06/2004 | US6759522 1-((3,4,5-trihydroxy-6-sulfomethyl-tetrahydropyran-2-yl)-),2 -(fatty acyl),3-(optionally fatty acyl)glycerol; dna polymerase inhibitors; anticancer agents |
07/06/2004 | US6759513 Death domain containing receptors |
07/06/2004 | US6759431 Compositions and methods for treating or preventing diseases of body passageways |
07/06/2004 | US6759430 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress |
07/06/2004 | US6759421 Indoline compounds, a process for their preparation and pharmaceutical compositions containing them |
07/06/2004 | US6759420 Low molecular weight, factor xa specific blood clotting inhibitors without side effects |
07/06/2004 | US6759418 6-(((2s)-2-(alkoxycabonyl)-4,4-difluoropyrrolidinyl)methyl)-1, 2, 3.4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylate, or acid derivatives, useful for treating migraine, and dural protein extravasation |
07/06/2004 | US6759417 Vascular endothelial growth factor receptor tyrosine kinase inhibitors; such as 7-amino-6-(1h-benzimidazol-2-yl)-3,4-dihydro-5h-imidazo(4,5-b)pyridin-5-one |
07/06/2004 | US6759413 Use of cox-2 inhibitors as gastroprokinetics |
07/06/2004 | US6759412 For producing drugs used for therapy of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis |
07/06/2004 | US6759404 Inhibiting gamma-secretase activity; treating diseases associated with beta-amyloid production, such as alzheimer's disease |
07/06/2004 | US6759400 Meiosis regulating compounds |
07/06/2004 | US6759396 Compositions based on a synergistic mixture of at least one VDR ligand and a retinoid |
07/06/2004 | US6759387 Delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue |
07/06/2004 | US6759208 Prevention, therapy disease; forming tritiated water; calibration |
07/06/2004 | US6759201 Method of identifying a neural progenitor cell by evaluating expression of daedalos |
07/06/2004 | US6759188 Method for producing interleukin 1 receptor antagonists, a therapeutic activity protein, from body fluids |
07/06/2004 | CA2312206C Novel bicyclic derivatives of amino-pyrazinones, process for preparing them and pharmaceutical compositions containing them |
07/06/2004 | CA2303594C Compounds for treating and preventing diabetic complications |
07/06/2004 | CA2278759C Process for preparing synthetic soil-extract materials and medicaments based thereon |
07/06/2004 | CA2140361C Composition and methods for decreasing muscle breakdown |
07/06/2004 | CA2088831C Photocurable glycosaminoglycan derivatives, crosslinked glycosaminoglycans and method of production thereof |
07/06/2004 | CA2085201C New pyridyl derivatives, pharmaceutical compositions containing these compounds and processes for preparing them |
07/01/2004 | WO2004055186A1 Guanosine triphosphate-binding protein-coupled receptor |
07/01/2004 | WO2004055185A1 Novel protein and dna thereof |
07/01/2004 | WO2004055184A1 GLUCOSE AND/OR FRUCTOSE TRANSPORTER NaGLT1 AND ITS GENE |
07/01/2004 | WO2004055002A1 Carbazole derivatives and their use as npy-5 antagonists |
07/01/2004 | WO2004054983A2 1-n-phenylamino-1h-imidazole derivatives as aromatase inhibitors |
07/01/2004 | WO2004054979A1 Jnk inhibitors |
07/01/2004 | WO2004054972A1 N-(indolethyl-)cacloamine compounds |
07/01/2004 | WO2004054620A1 Induction of tolerance through oral administration of a therapeutic agent coupled to a transporting agent |
07/01/2004 | WO2004054617A1 Preventives and/or remedies for central diseases |
07/01/2004 | WO2004054616A1 Antagonist and agonist binding to strong binding site of chemokine receptor |
07/01/2004 | WO2004054610A1 Vaccine for fish cold-water disease |
07/01/2004 | WO2004054594A1 Cell death inhibitor |
07/01/2004 | WO2004054574A1 Solid drug for oral use |
07/01/2004 | WO2004054566A1 Pregabalin derivatives for the treatment of fibromyalgia and other disorders |
07/01/2004 | WO2004054565A1 Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders |
07/01/2004 | WO2004054564A1 Gabapentin analogues for fibromyalgia and other related disorders |
07/01/2004 | WO2004054555A1 Novel dry powder inhalation system for transpulmonary administration |
07/01/2004 | WO2004054520A1 Whitening agent, skin preparation for external use and cosmetic |
07/01/2004 | WO2004054356A2 Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent |
07/01/2004 | WO2004026116A3 Use of etodoclac to treat hyperplasia |
07/01/2004 | WO2004017906A3 Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s) |
07/01/2004 | WO2004013093A3 Cytotoxic agents containing novel potent taxanes and their therapeutic use |
07/01/2004 | WO2004006865A3 Compounds, compositions, and methods |
07/01/2004 | WO2004002420A3 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use |
07/01/2004 | WO2003106385A3 Process for screening fungitoxic compounds |
07/01/2004 | WO2003103608A3 Neuroprotective synergy of erythropoietin and insulin-like growth factor |
07/01/2004 | WO2003093297A3 Protein kinase modulators and methods of use |
07/01/2004 | WO2003092605A3 Protease inhibitors |
07/01/2004 | WO2003086325A3 Cyanamides useful as reversible inhibitors of cysteine proteases |
07/01/2004 | WO2003051278A3 Nanoparticle delivery vehicle |
07/01/2004 | WO2003040366A3 Inhibitor oligonucleotides and their use for specific repression of a gene |
07/01/2004 | WO2003003986A3 Parathyroid hormone antibodies and related methods |
07/01/2004 | WO2002099083A3 Gfats as modifiers of the p53 pathway and methods of use |
07/01/2004 | WO2002015846A3 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
07/01/2004 | WO1998008480A3 Method of using tetracycline compounds for inhibition of nitric oxide production |
07/01/2004 | US20040127735 New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral |
07/01/2004 | US20040127708 antiviral activities; aids treatment |
07/01/2004 | US20040127707 Novel phthalazinones |
07/01/2004 | US20040127705 Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action |
07/01/2004 | US20040127689 activated haptens useful for generating immunogens to HIV protease inhibitors |
07/01/2004 | US20040127686 Signal transduction regulator binding protein for identifying modulators for prevention and treatment of cardiomyopic hypertrophy, heart failure and diabetes; drug screening |
07/01/2004 | US20040127576 Estrogen receptor modulators |
07/01/2004 | US20040127572 the prevention or amelioration of sleep-related breathing disorders such as sleep apnea |
07/01/2004 | US20040127567 cystic fibrosis; or a chronic inflammatory disorder, e.g., ulcerative colitis, Crohn's disease, chronic pancreatitis, asthma, rheumatoid arthritis or chronic gastritis; abrogated fetal lung surfactant biosynthesis |
07/01/2004 | US20040127564 inactivators of antigen-specific T cells; increased half-life |
07/01/2004 | US20040127562 Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
07/01/2004 | US20040127555 bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; treatment of A beta , IAPP, other amyloids, and alpha -synuclein or NAC fibrillogenesis |
07/01/2004 | US20040127552 Benzoaxathiepin derivatives and their use as medicines |
07/01/2004 | US20040127550 Medicament containing an effector of the glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy |
07/01/2004 | US20040127546 for treating or preventing diabetes, obesity, hyperlipidemia, digestive diseases, depression or urinary disturbances; beta 3-agonist |
07/01/2004 | US20040127544 Mannich base prodrugs of 3-(Pyrrol-2-yl-methylidene)-2-indolinone derivatives |
07/01/2004 | US20040127542 1-(Pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
07/01/2004 | US20040127539 Antiangiogenic combination therapy for the treatment of cancer |
07/01/2004 | US20040127538 having an excellent JNK inhibitory action |
07/01/2004 | US20040127537 Stable liquid parenteral parecoxib formulation |
07/01/2004 | US20040127533 Sulfonamide derivatives |
07/01/2004 | US20040127528 Metalloproteinase inhibitors |
07/01/2004 | US20040127527 Large conductance calcium-activated k channel opener |
07/01/2004 | US20040127513 For prophylaxis and therapy of chronic or acute inflammatory or autoimmune diseases, those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease |
07/01/2004 | US20040127498 Heterocyclic side chain containing, n-substituted metalloprotease inhibitors |
07/01/2004 | US20040127496 Imidazole-2-carboxamide derivatives as raf kinase inhibitors |
07/01/2004 | US20040127494 Sulfur compounds such as (2R)-2-[N-(4-Chlorobenzenesulfonyl)-N-(4-methoxybenzyl)amino]-4-methylpentanoic acid amide, used for prophylaxis of neurodegenarative disorders such as Alzheimer's Disease and Down's Syndrome |
07/01/2004 | US20040127492 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 |
07/01/2004 | US20040127485 1,4! - diazepane -1- carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists |
07/01/2004 | US20040127482 Substituted heterocycle fused gamma-carbolines |